Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David B Huang

Showing results (31-40 of 88) with videos related to

Pageof 9
Sort By:
Current Therapeutic Research, Clinical and Experimental|March 21, 2014
Linezolid effects on bacterial toxin production and host immune response: review of the evidenceBinh An Diep, Ozlem Equils, David B Huang, et al.
The Canadian Journal of Infectious Diseases & Medical Microbiology = Journal Canadien Des Maladies Infectieuses Et De La Microbiologie Medicale|March 13, 2018
<i>In Vitro</i> Activity of Iclaprim against Methicillin-Resistant <i>Staphylococcus aureus</i> Nonsusceptible to Daptomycin, Linezolid, or Vancomycin: A Pilot StudyDavid B Huang, Stephen Hawser, Curtis G Gemmell, et al.
Clinical Medicine Insights. Gastroenterology|May 17, 2014
Rifaximin therapy of irritable bowel syndromeHoonmo L Koo, Saman Sabounchi, David B Huang, et al.
Journal of Clinical Microbiology|December 17, 2009
K2 serotype Klebsiella pneumoniae causing a liver abscess associated with infective endocarditisAndres Rivero, Eric Gomez, David Alland, et al.
Dermatologic Therapy|December 2, 2004
Therapy of systemic fungal infectionsJashin J Wu, Katie R Pang, David B Huang, et al.
The American Journal of Gastroenterology|March 30, 2004
Enteroaggregative Escherichia coli: an emerging enteric pathogenDavid B Huang, Pablo C Okhuysen, Zhi-Dong Jiang, et al.
Dermatologic Therapy|December 2, 2004
Subcutaneous fungal infectionsKatie R Pang, Jashin J Wu, David B Huang, et al.
Dermatologic Clinics|April 20, 2005
Advances in antiviral therapyJashin J Wu, Katie R Pang, David B Huang, et al.
Clinical Therapeutics|April 30, 2019
A Pooled Analysis of the Safety and Efficacy of Iclaprim Versus Vancomycin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Patients With Intravenous Drug Use: Phase 3 REVIVE StudiesDavid B Huang, Stephanie Noviello, Barbara Balser, et al.
Journal of Medical Microbiology|May 4, 2019
The incidence and patient outcomes of ABSSSI by iclaprim MIC values in the phase 3 REVIVE trials for treatment of acute bacterial skin and skin structure infectionsDavid B Huang, Cedric Charrier, Chloé Le Bras, et al.
Pageof 9

Showing results (31-40 of 88) with videos related to

Sort By:
Pageof 9
Current Therapeutic Research, Clinical and Experimental|March 21, 2014
Linezolid effects on bacterial toxin production and host immune response: review of the evidenceBinh An Diep, Ozlem Equils, David B Huang, et al.
The Canadian Journal of Infectious Diseases & Medical Microbiology = Journal Canadien Des Maladies Infectieuses Et De La Microbiologie Medicale|March 13, 2018
<i>In Vitro</i> Activity of Iclaprim against Methicillin-Resistant <i>Staphylococcus aureus</i> Nonsusceptible to Daptomycin, Linezolid, or Vancomycin: A Pilot StudyDavid B Huang, Stephen Hawser, Curtis G Gemmell, et al.
Clinical Medicine Insights. Gastroenterology|May 17, 2014
Rifaximin therapy of irritable bowel syndromeHoonmo L Koo, Saman Sabounchi, David B Huang, et al.
Journal of Clinical Microbiology|December 17, 2009
K2 serotype Klebsiella pneumoniae causing a liver abscess associated with infective endocarditisAndres Rivero, Eric Gomez, David Alland, et al.
Dermatologic Therapy|December 2, 2004
Therapy of systemic fungal infectionsJashin J Wu, Katie R Pang, David B Huang, et al.
The American Journal of Gastroenterology|March 30, 2004
Enteroaggregative Escherichia coli: an emerging enteric pathogenDavid B Huang, Pablo C Okhuysen, Zhi-Dong Jiang, et al.
Dermatologic Therapy|December 2, 2004
Subcutaneous fungal infectionsKatie R Pang, Jashin J Wu, David B Huang, et al.
Dermatologic Clinics|April 20, 2005
Advances in antiviral therapyJashin J Wu, Katie R Pang, David B Huang, et al.
Clinical Therapeutics|April 30, 2019
A Pooled Analysis of the Safety and Efficacy of Iclaprim Versus Vancomycin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Patients With Intravenous Drug Use: Phase 3 REVIVE StudiesDavid B Huang, Stephanie Noviello, Barbara Balser, et al.
Journal of Medical Microbiology|May 4, 2019
The incidence and patient outcomes of ABSSSI by iclaprim MIC values in the phase 3 REVIVE trials for treatment of acute bacterial skin and skin structure infectionsDavid B Huang, Cedric Charrier, Chloé Le Bras, et al.
Pageof 9